GB-5267 is an autologous T-lymphocyte cell therapy genetically modified to express an anti-MUC16 chimeric antigen receptor with 4-1BB and CD3zeta signaling domains, and to secrete interleukin 18. The engineered cells recognize membrane-bound MUC16 on tumor cells and kill them, and are being studied in platinum-resistant ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.